This is not the most recent version of the article. View current version (20 JUN 2013)

Intervention Protocol

High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients

  1. Michaela Rancea1,*,
  2. Ina Monsef1,
  3. Bastian von Tresckow2,
  4. Andreas Engert1,
  5. Nicole Skoetz1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 9 NOV 2011

DOI: 10.1002/14651858.CD009411


How to Cite

Rancea M, Monsef I, von Tresckow B, Engert A, Skoetz N. High-dose chemotherapy followed by autologous stem cell transplantation for refractory/relapsed Hodgkin lymphoma patients (Protocol). Cochrane Database of Systematic Reviews 2011, Issue 11. Art. No.: CD009411. DOI: 10.1002/14651858.CD009411.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Cologne, Department I of Internal Medicine, Cologne, Germany

*Michaela Rancea, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. michaela.rancea@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 9 NOV 2011

SEARCH

This is not the most recent version of the article. View current version (20 JUN 2013)

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The main objective of this review is to find the best available treatment with high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) for patients with primary refractory or first relapsed HL. We will analyse overall survival (OS) as the primary endpoint; and will also analyse progression-free survival (PFS), response rate, treatment-related mortality (TRM), adverse events (AE), and quality of life (QoL) as secondary endpoints.